With its lead product Rhucin (recombinant C1 inhibitor) under regulatory review in Europe and its cash balance dwindling rapidly, Pharming Group NV is battening down the hatches by spinning out DNage BV, a firm it acquired in 2006. (BioWorld International)
CHICAGO - Venture capital investment in nanomedicine hit $64 million in the first quarter of this year, compared with a total of $135 million for the whole of 2009. Deal completion is also well up on last year. The first quarter total represents seven transactions, and just 14 were completed in 2009. (BioWorld Today - 2010 BIO)
CHICAGO - Does the successful translation of science into innovative therapies require more and better science or better management of supporting activities, such as data management and collaboration? (BioWorld Today - 2010 BIO)
